Do you want to read an article? Please log in or register.
Efficacy of Onalespib a Long-acting Second Generation HSP90 Inhibitor as a Single Agent and in Combination with Temozolomide Against Malignant Gliomas
Central Nervous System Tumors
Related content
Central Nervous System Tumors
Phase II study to evaluate the safety and efficacy of intravenous palonosetron (PAL) in primary malignant glioma (MG) patients receiving standard radiotherapy (RT) and concomitant temozolomide (TMZ)
Support Care Cancer.
Affronti ML, Woodring S, Allen K, Kirkpatrick J, Peters KB, Herndon JE 2nd, McSherry F, Healy PN, Desjardins A, Vredenburgh JJ, Friedman HS
doi: 10.1007/s00520-016-3276-1.
LeukemiaLymphoma
Time for a New Standard: Single Agent Ibrutinib shows Long-Term Efficacy and Safety in Previously Treated MCL and CLL1-4
This healthbook SPECIAL is supported by Janssen-Cilag AG
Lung, Respiratory and Thoracic Cancer
A multicentre randomised phase III trial comparing pembrolizumab vs single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial
Ann Oncol.
Popat S, Curioni-Fontecedro A, Dafni U, Shah R, O'Brien M, Pope A, Fisher P, Spicer J, Roy A, Gilligan D, Gautschi O, Nadal E, Janthur WD, Castro RL, Campelo RG, Rusakiewicz S, Letovanec I, Polydoropoulou V, Roschitzki-Voser H, Ruepp B, Gasca-Ruchti A, Peters S, Stahel R
doi: 10.1016/j.annonc.2020.09.009.
Lung, Respiratory and Thoracic Cancer
A multicentre randomised phase III trial comparing pembrolizumab vs single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial
Ann Oncol
Popat S, Curioni-Fontecedro A, Dafni U, Shah R, O'Brien M, Pope A, Fisher P, Spicer J, Roy A, Gilligan D, Gautschi O, Nadal E, Janthur WD, Castro RL, Campelo RG, Rusakiewicz S, Letovanec I, Polydoropoulou V, Roschitzki-Voser H, Ruepp B, Gasca-Ruchti A, Peters S, Stahel R
doi: 10.1016/j.annonc.2020.09.009
RECOMMENDED
Lung, Respiratory and Thoracic Cancer
BRAF V600E mutation and MET amplification as resistance pathways of the second-generation anaplastic lymphoma kinase (ALK) inhibitor alectinib in lung cancer
★ 1
Recommended by
Dr Wolf-Dieter Janthur, Faculty Member
Lung Cancer.
Shi R, Filho SNM, Li M, Fares A, Weiss J, Pham NA, Ludkovski O, Raghavan V, Li Q, Ravi D, Cabanero M, Moghal N, Leighl NB, Bradbury P, Sacher A, Shepherd FA, Yasufuku K, Tsao MS, Liu G
doi: 10.1016/j.lungcan.2020.05.018.
Gastrointestinal Cancer
Safety and Tolerability of Anti-Angiogenic Protein Kinase Inhibitors and Vascular-Disrupting Agents in Cancer: Focus on Gastrointestinal Malignancies
Drug Saf.
Procaccio L, Damuzzo V, Di Sarra F, Russi A, Todino F, Dadduzio V, Bergamo F, Prete AA, Lonardi S, Prenen H, Palozzo AC, Loupakis F
doi: 10.1007/s40264-018-0776-6.
Lung Cancer
Molecular Diagnostic and Precision Medicine in Non-Small Cell Lung Cancer. An Update on the Treatment of the Most Important Actionable Oncogenic Driver Alterations.
1Department of Medical Oncology, University Hospital Basel, Basel, Switzerland.
Central Nervous System TumorsRadio-Oncology
Efficacy of bevacizumab therapy for unresectable malignant glioma: A retrospective analysis
Mol Clin Oncol.
Yonezawa H, Hirano H, Uchida H, Habu M, Hanaya R, Oyoshi T, Sadamura Y, Hanada T, Tokimura H, Moinuddin F, Arita K
doi: 10.3892/
Lung, Respiratory and Thoracic Cancer
Immune checkpoint inhibitors in thoracic malignancies: Review of the existing evidence by an IASLC expert panel and recommendations
J Thorac Oncol.
Remon J, Passiglia F, Ahn MJ, Barlesi F, Forde PM, Garon EB, Gettinger S, Goldberg SB, Herbst RS, Horn L, Kubota K, Lu S, Mezquita L, Paz-Ares L, Popat S, Schalper KA, Skoulidis F, Reck M, Adjei AA, Scagliotti GV
doi: 10.1016/j.jtho.2020.03.006.